Zucaglim M3 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3mg and Metformin 1000mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic beta-cell insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and increasing peripheral insulin sensitivity, promoting better glucose uptake in muscle tissues. The prolonged-release formulation ensures a steady plasma concentration, minimizing peak-related side effects and enhancing patient compliance through once-daily dosing. Zucaglim M3 Forte is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal glycemic targets. It is essential to monitor blood glucose levels regularly and adjust dosage accordingly under medical supervision. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued therapy. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in those with severe renal dysfunction, metabolic acidosis, or hypersensitivity to its components. This combination therapy offers a synergistic approach to glycemic management, improving patient outcomes in type 2 diabetes mellitus when used as part of a comprehensive treatment plan including lifestyle modifications.